To check a drug approval claim, start with Drugs@FDA and match the exact product to its approval record and labeling. It's the primary FDA drug approval database for human medicines, but some products require a different FDA database.
A product name can match while the advertised use doesn't. An official listing can exist without establishing FDA approval.
We start with the product, then follow the record far enough to see what it supports.
Key Takeaways
- Start with Drugs@FDA and match the exact product, application number, approval history, and labeling. Check that the approved use and decision date support the claim.
- Use the Orange Book to compare generic products by ingredient, strength, dosage form, and route. Its therapeutic equivalence codes answer a different question from whether a drug is approved.
- Use the Purple Book for biological product licenses and recorded biosimilar or interchangeability relationships.
- An NDC listing or DailyMed label doesn't establish FDA approval. A failed search also doesn't prove a product is unapproved, since the product may be listed under another name or fall outside that database's scope.
Start with the FDA drug approval database
Drugs@FDA includes many FDA-approved products marketed as prescription drugs, over-the-counter drugs, and biological therapeutic products. It covers most drug products approved since 1939.
The FDA's drug approvals and databases directory provides access to this resource and related systems. For most products approved since 1998, it includes patient information, labels, approval letters, and reviews.
Search by name, ingredient, or application number
Before searching, save the claim's wording and publication date. Keep the product's strength, dosage form, manufacturer, and active ingredient attached to it.
Search by drug name, active ingredient, or application number. An application number is often the clearest route when a seller supplies one.
The prefixes identify different applications: NDA means New Drug Application, ANDA means Abbreviated New Drug Application, and BLA means Biologics License Application.
A brand-name search may produce several strengths or formulations. Open the entry that matches the product being discussed. A familiar name alone doesn't establish that you've found the right record.
Open the approval history and documents
Read beyond the search-result heading. Compare the application holder, active ingredient, strength, dosage form, and route of administration with the product claim.
Then open the approval history, available approval letters, and labeling. An original approval and a later approval for an additional use can carry different dates.
We distinguish the application's history from the product's marketing status. A discontinued listing doesn't, by itself, establish that FDA withdrew approval for safety reasons.
Save the record's application number, approval letters, and relevant labeling. Those details give readers a source they can retrace, rather than a screenshot without context.
Match the claim to the approved use
Approval has a scope. It applies to a particular product under conditions described in its approved labeling.
Read the label's indications and usage section. Compare the condition, patient population, dosage form, and route with the claim. Approval for one condition doesn't establish approval for every use discussed in an advertisement or news story.
Dates matter here. A claim about approval last year needs the decision available then, not merely a newer label showing an expanded indication.
We also separate a drug's approval status from a clinician's prescribing decision. A medicine can be prescribed for an off-label use, but that doesn't make the use FDA approved.
An approval record also doesn't prove that a product sold online is authentic or that a particular seller is legitimate.
The finding should stay narrow: the record supports approval of this product for these uses. It doesn't establish every benefit attached to the product's name.
Find generic equivalents in the Orange Book
The FDA's Orange Book identifies drug products approved on the basis of safety and effectiveness. It also provides therapeutic equivalence evaluations for multisource prescription drugs, helping readers assess generic drugs.
Compare the formulation before the name
Search using the active ingredient, trade name, applicant, or application number. Then compare the strength, dosage form, and route.
The same ingredient can appear in products with different release characteristics or methods of administration. Those differences matter when judging whether a generic matches the product in a claim.
The database also identifies reference products used in generic-drug evaluations. We use that relationship to keep the comparison tied to the relevant formulation.
An ingredient match starts the comparison. The product details determine whether the comparison holds.
Read equivalence codes without overclaiming
A codes indicate FDA's determination of therapeutic equivalence under its evaluation criteria. B codes mean FDA hasn't made that determination for other pharmaceutically equivalent products.
A B code doesn't mean the drug is unapproved. Approval and therapeutic equivalence answer different questions.
The database helps identify FDA-evaluated generic options. It doesn't replace patient-specific prescribing advice or the state rules governing pharmacy substitution.
We keep that distinction visible because a claim about an approved generic can become misleading when it implies every formulation is interchangeable.
Use the Purple Book for biological products
The database lists FDA-licensed products, including biosimilars and interchangeable biological products. It's the relevant source when a claim concerns those relationships.
A biosimilar is highly similar to its reference product, with no clinically meaningful differences in safety, purity, and potency. Interchangeability requires a separate FDA determination.
Compare the product, its reference product, and its recorded status. A similar name or shared use doesn't establish biosimilarity or interchangeability.
Drugs@FDA includes biological therapeutic products, but it isn't the only FDA record system for biologics. The product type determines where the relevant licensing information appears.
We use the database listing to establish the documented licensing relationship, rather than treating a manufacturer's description as the decision itself.
Separate an NDC listing from approval
The NDC Directory contains listing information for finished and unfinished prescription and OTC drugs, including listed compounded drugs. An NDC, or National Drug Code, identifies a listed product or package. Its presence doesn't establish approval.
Use the listing to identify the product
Use the NDC codes on the packaging to locate the corresponding entry. Compare the labeler, ingredient, strength, dosage form, route, and package information.
That can help distinguish products with similar names. It can also connect packaging information with an application number that leads to an approval record.
Read the entry as listing information. FDA receives drug-listing submissions from businesses, and the directory contains both approved and unapproved products.
For compounded products, a listing doesn't establish that FDA reviewed and approved the preparation for safety and effectiveness.
Keep registration and listing in their categories
An NDC assignment doesn't mean FDA approved the drug. Establishment registration and product listing don't substitute for an approval decision either.
Phrases such as "FDA registered" or "FDA compliant" need to be read literally. Neither phrase establishes that FDA approved the advertised product or use.
Clearance claims concern a different regulatory question. If the product is a medical device, our guide to FDA approval and clearance explains the relevant device records.
We don't carry a term across product categories and assume it means the same thing.
Read drug labeling through DailyMed
The National Library of Medicine hosts DailyMed, a collection of drug labeling that includes package inserts submitted to FDA by companies.
FDA's prescription-drug labeling resources explain the available labeling sources. The collection helps identify ingredients, warnings, dosage instructions, and labeling tied to a particular product.
An entry doesn't independently establish FDA approval. The collection includes products beyond FDA-approved human drugs.
There's another distinction: "in use" labeling can differ from the latest FDA-approved labeling. For an approval claim, compare it with the approval record and approved label in Drugs@FDA.
We compare the labeler, product identifiers, and revision dates before treating two documents as equivalent. A newer-looking page isn't necessarily evidence of a newer FDA approval.
A label supplies detail. The approval record establishes the regulatory decision. Later safety information may also change how an older approval should be described.
Understand what a missing result means
A failed search doesn't establish that a product is unapproved. It establishes that the search didn't return a matching record.
Start by checking spelling and the active ingredient. A product may appear under another brand name or application holder. Repeating the same search won't resolve an identity mismatch.
Then reconsider the product category. Biological products may require licensing records outside the initial search. Animal medicines belong in separate FDA records. A device claim needs device databases.
Some OTC drugs are legally marketed under an applicable OTC monograph rather than an individually approved application. That pathway doesn't make a product individually FDA approved.
We distinguish an unmatched search, a product outside the database's scope, and evidence contradicting an approval claim. Those are different findings. The wording should show which one the available records support.
Download records without losing their context
The FDA dataset is available as a ZIP download containing 12 tab-delimited tables. The FDA updates the files on weekday mornings. The downloadable records include drugs approved since 1939, though older entries don't all have the same level of detail.
The July 16, 2025 date on an older data.gov catalog entry isn't the current dataset date. The FDA's data-files page showed an October 16, 2026 snapshot.
The tables separate applications, products, submissions, and other information. Preserve application and product identifiers when joining records. Otherwise, an approval date or document can become attached to the wrong formulation.
Separate downloadable data files are available for these records through the separate downloadable data files.
DrugBank's Clinical API provides structured US product data. Its fields include product names, ingredients, NDC codes, NDA, ANDA, and BLA application numbers, strengths, routes, and forms. Its US Drug Labels module imports labeling.
The Clinical API can organize larger searches, but verify US Drug Labels output against FDA records and labeling. For a disputed approval claim, follow the identifiers to the original FDA decision and labeling.
Keep each database’s purpose separate
This comparison helps distinguish an identification record from an approval finding.
| Source | Main purpose | Important limit |
|---|---|---|
| Drugs@FDA | Approval history and documents | Match the exact product and use |
| Orange Book | Approved drugs and therapeutic equivalence | Ingredient matches aren't enough |
| Purple Book | Biological licenses and biosimilar relationships | Biosimilar doesn't automatically mean interchangeable |
| NDC Directory | Product and package listings | Listing doesn't establish approval |
| DailyMed | Company-submitted drug labeling | Inclusion doesn't establish approval |
The strongest evidence connects these records without flattening their differences. A listing identifies. A label describes. An approval document records a decision.
Frequently Asked Questions
What does Drugs@FDA show?
Drugs@FDA includes many FDA-approved human drug products and their available approval histories, letters, reviews, and labeling. Match the record to the exact product and compare its approved use with the claim.
Does an NDC listing mean a drug is FDA approved?
No. The NDC Directory contains listing information for approved and unapproved products, and an NDC identifies a listed product or package rather than an approval decision.
How can I check whether a generic matches a drug?
Use the Orange Book to compare the active ingredient, strength, dosage form, and route. Its A and B codes describe FDA's therapeutic equivalence determination, not whether a product is approved.
Where should I check claims about biosimilars?
Use the Purple Book to review biological product licenses and recorded relationships with reference products. Interchangeability requires a separate FDA determination.
What does it mean if a search finds no result?
A failed search means the search didn't return a matching record; it doesn't establish that the product is unapproved. Check spelling and the active ingredient, then consider whether another FDA database covers that product category.
Keep the finding tied to the record
A drug approval claim is supported when the exact product, documented decision, and claimed use agree. A matching name or official-looking number can't carry that conclusion alone.
We keep the scope of the finding attached to the evidence. When the record supports a narrower statement than the advertisement, report the narrower statement.
That is how an FDA database search becomes a supported conclusion rather than another claim passed along.